Areas of Focus

Bladder cancer and other genitourinary tumors

Bladder Cancer (BC) ranks 11th in the most common malignant tumors, with nearly 549,000 new cases and over 199,000 death worldwide in 2018. The numbers of new BC patients and death in 2014 were 71,000 and 25,000 respectively in China. In recent years, the incidence has been increasing with an annual growth rate near 5%.

Non-muscle invasive bladder cancer (NMIBC, tumors confined to the bladder mucosa and sub mucosa layers without invasion to the muscle layer) accounts for 70-80% of newly diagnosed bladder cancer patients.

Currently, the common treatment of NMIBC is Trans-Urethral Resection of Bladder Tumor (TURBT). Because of high recurrence (60-70%) after TURBT surgery, intravesical chemotherapy or immunotherapy is usually required after the surgery. However, intravesical therapy is quite painful and chemotherapy may result in drug resistance. Therefore, there is an urgent need for drugs with novel mechanism and treatment regimen.

In addition to bladder cancer, Asieris also focuses on the development of new drugs for other urogenital cancers, such as cervical cancer, ovarian cancer, prostate cancer, and renal carcinoma, etc.

Multi drug resistant infection

Bladder Cancer (BC) ranks 11th in the most common malignant tumors, with nearly 549,000 new cases and over 199,000 death worldwide in 2018. The numbers of new BC patients and death in 2014 were 71,000 and 25,000 respectively in China. In recent years, the incidence has been increasing with an annual growth rate near 5%.

Non-muscle invasive bladder cancer (NMIBC, tumors confined to the bladder mucosa and sub mucosa layers without invasion to the muscle layer) accounts for 70-80% of newly diagnosed bladder cancer patients.

Currently, the common treatment of NMIBC is Trans-Urethral Resection of Bladder Tumor (TURBT). Because of high recurrence (60-70%) after TURBT surgery, intravesical chemotherapy or immunotherapy is usually required after the surgery. However, intravesical therapy is quite painful and chemotherapy may result in drug resistance. Therefore, there is an urgent need for drugs with novel mechanism and treatment regimen.

In addition to bladder cancer, Asieris also focuses on the development of new drugs for other urogenital cancers, such as cervical cancer, ovarian cancer, prostate cancer, and renal carcinoma, etc.